Updated:
Zymeworks Inc.
Zymeworks Inc. was founded in 2003 in Vancouver, Canada, and went public on the NYSE in 2017.
Zymeworks Inc.
Zymeworks Inc. was founded in 2003 in Vancouver, Canada, and went public on the NYSE in 2017. Kenneth Galbraith took over as CEO in January 2021, replacing co-founder Ali Tehrani, who transitioned to board chair. The company is a publicly traded biotechnology firm, but it operates with the R&D-intensive architecture of a family-office-style entity given its dual mandate of internal drug development and platform licensing. The company's core technology is the Azymetric platform, which enables the design of bispecific antibodies. Zymeworks also developed a controlled-release antibody-drug conjugate platform called ZymeLink. These platforms have led to partnerships with major pharmaceutical companies, including a notable 2021 agreement with Jazz Pharmaceuticals that included an equity investment and development of multiple bispecific antibodies (per Zymeworks, 2021). The firm also inked a 2022 deal with Daiichi Sankyo for its HER2-targeting bispecific antibody zanidatamab (per the firm, 2022). Zymeworks has a pipeline that includes both partnered and wholly-owned programs, primarily in oncology. The company's lead asset, zanidatamab (ZW25), targets HER2-positive cancers and has received Breakthrough Therapy Designation from the FDA. As of 2024, Zymeworks had over 200 employees and maintained its HQ in Vancouver, with additional operations in Seattle. The firm reported approximately $508 million in cash and investments as of September 2024 (per SEC filing, November 2024). Structurally, Zymeworks stands out as a hybrid: a public company with a deep technology platform licensed by multiple large pharma partners. This model combines the risk profile of early-stage biotech with the revenue potential of a platform company, shared across multiple alliances.
General information
Firm type
other
Year founded
2003
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Vancouver
Corporate office
Vancouver, British Columbia, Canada
Principals
Kenneth A. Galbraith
Chief Executive Officer
Neil A. Klompas
President and Chief Operating Officer
Shane C. M. Campbell
Chief Business Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Zymeworks?
As a publicly traded company, Zymeworks' board of directors oversees corporate strategy, while CEO Kenneth Galbraith leads executive decisions. The scientific direction is shaped by the founding team and chief scientific officer.
How does Zymeworks source its proprietary technology?
Zymeworks developed its bispecific antibody platform internally over two decades. The Azymetric platform is its core intellectual property, enabling precise engineering of antibodies that can bind two targets simultaneously.
Is Zymeworks structured as a family office or as a venture firm?
Zymeworks is a publicly traded biotechnology company, not a family office or venture firm. However, its long-term R&D focus and partnership-heavy business model resemble the patient capital approach of a family office.
Does Zymeworks participate in fund commitments or only direct deals?
Zymeworks is an operating biotech company; it does not deploy capital as an investment manager. Its partnerships with Jazz Pharmaceuticals and Daiichi Sankyo involve upfront payments, equity investments, and milestone revenues.
Which investment stages does Zymeworks typically target?
Zymeworks focuses on preclinical and clinical-stage drug development. It advances its own pipeline to early-phase clinical trials before seeking partners for late-stage development and commercialization.
What investment sectors does Zymeworks explicitly avoid?
Zymeworks concentrates exclusively on oncology and immuno-oncology. It does not engage in other therapeutic areas such as neurology, infectious disease, or rare diseases.
How is Zymeworks related to other entities?
Zymeworks is a standalone public company (NYSE: ZYME). It has subsidiary operations in the U.S. through Zymeworks USA Inc. and historically had a collaboration with Eli Lilly, which was terminated.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: